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Available online 21 April 2017Sodium valproate is a commonly used antiseizure drug with broad indications for different seizuretypes and ep-
ilepsy syndromes. Well-recognised side effects include weight gain, tremor, dizziness, and unsteadiness. Non-
hyperammonaemic parkinsonism, with or without cognitive impairment, is a rare adverse effect of sodium
valproate. We present the case of a sixty year-old lady with a generalized seizure disorder, treated with phenyt-
oin, valproate, lamotrigine and clonazepam. Following withdrawal of phenytoin she developed an akinetic-rigid
syndrome, with ataxia and marked cognitive impairment. Extensive investigation failed to identify a cause.
Serum ammonia and valproate levels were normal. Hypothesizing this might be valproate encephalopathy,
valproate was rapidly substituted with levetiracetam. Her severe motor symptoms resolved within two weeks
and cognitive impairment markedly improved. Valproate-induced encephalopathy, with or without
hyperammonaemia and liver toxicity are typically recognizable for their temporal relationbetween the start of ther-
apy with valproate and emergence of the clinical syndrome. Reversible disorders of motor function and cognition
attributable to valproate are well described, but few cases have been reported presenting years after starting treat-
ment. Given the insidious progression, delayed onset, lack of association with drug levels or presence of
hyperammonaemia, a high index of suspicion is needed to make the diagnosis.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Serious adverse events in patients treated with sodium valproate are
uncommon. The risk of such events occurring is considerably increased
when valproate is administered as part of a poly-therapy regimen, in
the very young (under two years of age), and in those with unsuspected
defects of theurea cycle [1].Manyof the adverse events that arisewith so-
dium valproate are quickly detected because of the temporal association
between starting the drug and the onset of symptoms, which may
range from weight gain and tremor, to the more serious apathy and
drowsiness seen in hyperammonaemic valproate-encephalopathy or
valproate-induced liver toxicity. Non-hyperammonaemic parkinsonism,
with or without cognitive impairment, is a rare adverse effect of sodium
valproate therapy. We report the case of a woman who developed an
akinetic-rigid syndrome with ataxia and cognitive impairment after
many years of treatment on a stable dose of sodiumvalproate, and review
of the relevant literature.ana Galizia).
. This is an open access article under2. Case report
A 60-year-old woman was referred to our epilepsy clinic for follow
up of her childhood-onset epilepsy, characterized by absences, general-
ized tonic-clonic seizures, and possible myoclonic jerks. Video-EEG
telemetry recording undertaken to conﬁrm syndromic classiﬁcation
showed interictal spike-waves and polyspike-waves complexes,
supporting the diagnosis of an idiopathic (genetic) generalized epilepsy.
She had been seizure-free prior to referral for 20 years on a combination
of clonazepam (total daily dose of 1.5mg), sodium valproate (total daily
dose of 1700 mg), lamotrigine (total daily dose of 100mg) and phenyt-
oin (total daily dose of 200 mg). She also had longstanding anxiety and
depression, and breast cancer diagnosed in 2003, treated with wide
local excision and local radiotherapy. She has one sonwith learning dis-
abilities and lives with her mother who is well at 94 years of age.
In view of her ongoing seizure freedom, the EEG ﬁndings and to sim-
plify her drug regimen, phenytoin was gradually withdrawn and
stopped. Two months later, she complained of new confusion and un-
steadiness, with falls, intermittent slurring of speech and a change in
handwriting. Shewas noted to have amild, bilateral upper limb tremor.
Her drug levels were within therapeutic range.
Her symptoms progressed resulting in several presentations to
her local emergency department with recurrent falls and on onethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lepsy clinic she was noted to have hypomimia and dysarthria, with
rest tremor and cogwheel rigidity, in keeping with a Parkinsonian
syndrome. She could not stand unaided and had a broad-based,
shufﬂing gait. Her mother reported the patient was more forgetful,
missing appointments and repeatedly asking what time of the day
it was.
Blood investigations, including vitamin B12 and folate, anti-neuronal
and paraneoplastic antibodies, were all within normal limits or negative.
Notably, serum valproate level was 99 mg/L, serum ammonia was 17
μmol/L (normal range 9–30 μmol/L) and liver function tests were normal.
lamotrigine level was 12mg/L (range 3-15mg/L) and phenytoin was un-
detected. Analysis of cerebrospinal ﬂuid was unremarkable and bio-
markers for prion disease were negative. Magnetic resonance imaging
of the brain showed a degree of generalized cerebral and cerebellar atro-
phy. The hippocampi were thought to be a little small, possibly withmid-
dle cerebellar peduncle and pontine atrophy. Electroencephalogram
showedmildly slow backgroundwith no evidence of subclinical seizures.
She scored 75/100 on the Addenbrooke's Cognitive Examination (ACE-R),
which was much lower compared to formal neuropsychometric assess-
ments performed in 1989 and 2011, which showed essentially normal
proﬁles.
Given the unusual clinical picture of progressive akinetic-rigid syn-
drome, ataxia and cognitive decline, and the timing of symptoms follow-
ing withdrawal of phenytoin, it was hypothesized this may represent
non-hyperammonaemic valproate encephalopathy.
The patient was admitted to our Neurology ward for rapid re-
placement of valproate with levetiracetam. On admission her Uniﬁed
Parkinson's Disease Rating Scale score was 48 and ACE-R score was
49/100. The drug changes were made successfully over a few days
without seizure relapse. Resolution of the extrapyramidal movement
disorder and improvement of her cognitive impairment was noted
by two weeks following withdrawal of valproate. ACE-R score im-
proved to 89/100 by the time of discharge. Outpatient review has
shown ongoing improvements regaining full independence for activ-
ities of daily living and she has remained seizure free since.
3. Discussion
Sodium valproate is a widely used antiseizure drug used for a
broad range of epilepsy syndromes and seizure-types. Tremor is a
common adverse effect of valproate on the central nervous system,
with less common side effects including headache, blurred vision,
dizziness, nystagmus, and unsteadiness [1]. Occurrence of these
and more serious adverse events during treatment with valproate
is inﬂuenced by co-administration of other drugs that inﬂuence
valproate pharmacokinetics and pharmacodynamics, underlying
disorders of the urea cycle, and individual susceptibility to adverse
events.
Valproate-associated encephalopathy is a well-recognized ad-
verse event, often associated with hyperammonaemia and typiﬁed
by the development of apathy, drowsiness and impaired cognition.
This idiosyncratic reaction is by deﬁnition unpredictable and not al-
ways associated with valproate dose or plasma levels, abnormal liver
function, or raised serum ammonia levels. It has often been described
occurring shortly after the introduction of sodium valproate, with
rapid resolution of encephalopathy following withdrawal of the
drug [2]. Valproate-induced liver toxicity is rare, occurring in rough-
ly 1 in 20,000 patients. It typically presents with apathy, drowsiness,
vomiting, and increased seizure frequency. Deranged liver function
tests may lag the clinical presentation, so clinicians need to be
aware of this serious adverse reaction and stop the drug if they sus-
pect the diagnosis [1].
Less well-recognized is valproate-associated encephalopathy
without hyperammonaemia presenting with a parkinsonian syn-
drome, with or without cognitive impairment. To date 28 adultpatients have been described in the literature presenting with an
akinetic-rigid syndrome that resolved on stopping sodium valproate
[3–5]. Typically symptoms developed shortly after starting or in-
creasing the dose of sodium valproate (10 days to one week). Few
of the reported cases developed symptoms after years of stable treat-
ment [3,4]. To our knowledge our case is the ﬁrst to be reported in
which symptoms developed after 20 years on a stable dose. Given
the insidious progression of symptoms and lack of association with
valproate dosage, drug levels, or presence of hyperammonaemia, a
high index of suspicion is needed to make the diagnosis of
valproate-associated encephalopathy in patients presenting with
an extra-pyramidal syndrome. As in our case, almost all patients
who stopped valproate showed dramatic recovery within weeks,
with most improvement seen within six months.
The mechanisms by which sodium valproate causes encephalop-
athy and parkinsonism remain unknown but are likely to bemultiple
[3]. Commonly cited mechanisms include effects on mitochondrial
metabolism by inhibition of mitochondrial fatty acid B-oxidation
and effects on the urea cycle, and through inhibition of GABA degra-
dation within the basal ganglia. Paradoxically, valproate has been
used to improve symptoms of parkinsonism without adverse effect
[3]. A number of reported cases had normal SPECT imaging suggest-
ing that valproate does not cause parkinsonism through loss of dopa-
minergic neurons [3], but some patients do appear to respond to
dopamine replacement therapy [4,5].
It is difﬁcult to know what role our patient's other antiseizure
medication may have played in her clinical presentation. Phenytoin
had been stopped entirely just before the onset of her symptoms.
Phenytoin is known to increase valproate metabolism and we
hypothesized that withdrawal of phenytoin may have led to a rela-
tive rise in valproate levels, even though these remained within the
therapeutic range. There is a well-recognized interaction between
lamotrigine and valproate, with valproate increasing lamotrigine
levels by slowing its metabolism, while lamotrigine may increase
metabolism of valproate by inducing liver enzymes. It is unclear
what contribution, if any, lamotrigine may have had to the clinical
picture we observed in our patient.
Interpretation of ammonia levels reported in the context of
valproate encephalopathy is challenging. Many reports and case se-
ries do not report ammonia levels and differences in methodology
make their interpretation difﬁcult. In animal studies the presence
of valproate lowers levels of ammonia required to cause encephalop-
athy compared to animals not given valproate [6]. Administration of
carnitine allows higher levels of serum ammonia to be tolerated
without causing encephalopathy, an effect that is diminished in the
presence of valproate.
4. Conclusion
Many practitioners are familiar with valproate encephalopathy pre-
senting with ﬂuctuating level of consciousness, with or without raised
ammonia levels and impaired liver function. Although our case had
many of the clinical features of Parkinsonism, including rest tremor,
hypomimia, bradykinesia, and cogwheel rigidity, her marked ataxia and
rapidly evolving cognitive impairmentmade us suspicious for an alterna-
tive cause of her symptoms. Our case highlights a less well-recognized
presentation of valproate encephalopathy, which resolved onwithdrawal
of the drug.
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